United States was the largest of Sotera Health Co’s 4 reported lines in fiscal 2025, at $629.54M — 54% of $1.16B.
| Geography | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| United States | $579.02M | $590.97M | $616.68M | $629.54M | |||
| Canada | $188.74M | $192.05M | $208.89M | $221.95M | |||
| Europe | $166.03M | $187.54M | $196.01M | $232.18M | |||
| Other | $69.90M | $78.73M | $78.86M | $79.95M | |||
| Total | $1.00B | $1.05B | $1.10B | $1.16B |
In fiscal 2025, which ended December 31, 2025, the 4 regions Sotera Health Co reported in this breakdown added up to $1.16B. That was up 5.7% from $1.10B in fiscal 2024. United States was the largest region, at $629.54M or 54.1% of the total, followed by Europe ($232.18M, 20.0%) and Canada ($221.95M, 19.1%). Together, the two largest regions made up 74.1% of this total.
Compared with fiscal 2024, Europe grew the fastest, rising 18.5% to $232.18M. Every sizeable region reported in both years grew. Over fiscal 2022 to 2025, revenue across these regions went from $1.00B to $1.16B, a compound annual growth rate of 5.1%. United States' share of the total fell from 57.7% to 54.1% over the same years.
This breakdown covers every fiscal year from 2019 to 2025, as reported in Sotera Health Co's annual filings.
Sterigenics was the largest of Sotera Health Co’s 3 reported lines in fiscal 2025, at $755.78M — 65% of $1.16B.
| Segment | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Sterigenics | $626.65M | $667.13M | $697.85M | $755.78M | |||
| Nelson Labs | $223.40M | $221.70M | $229.23M | $220.22M | |||
| Nelson Labs | — | — | — | — | |||
| Nordion | $147.50M | $153.75M | $171.29M | $182.82M | |||
| Total | $997.55M | $1.04B | $1.10B | $1.16B |
In fiscal 2025, which ended December 31, 2025, the 3 segments Sotera Health Co reported in this breakdown added up to $1.16B. That was up 5.5% from $1.10B in fiscal 2024. Sterigenics was the largest segment, at $755.78M or 65.2% of the total, followed by Nelson Labs ($220.22M, 19.0%) and Nordion ($182.82M, 15.8%). Together, the two largest segments made up 84.2% of this total.
Compared with fiscal 2024, Sterigenics grew the fastest, rising 8.3% to $755.78M. Nelson Labs fell the most, down 3.9% to $220.22M. Over fiscal 2022 to 2025, revenue across these segments went from $997.55M to $1.16B, a compound annual growth rate of 5.1%. Sterigenics' share of the total rose from 62.8% to 65.2% over the same years.
The table also keeps 1 segment that Sotera Health Co no longer reports, so earlier years can still be read on their original basis; use "Show 1 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2019 to 2025, as reported in Sotera Health Co's annual filings.
Point In Time was the largest of Sotera Health Co’s 2 reported lines in fiscal 2025, at $755.78M — 77% of $976.00M.
| Timing of Transfer of Good or Service | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Point In Time | $626.65M | $667.13M | $697.85M | $755.78M | |||
| Over Time | $223.40M | $221.70M | $229.23M | $220.22M | |||
| Total | $850.05M | $888.83M | $927.09M | $976.00M |
In fiscal 2025, which ended December 31, 2025, the 2 revenue lines Sotera Health Co reported in this breakdown added up to $976.00M. That is less than the $1.16B in its breakdown by region, so these revenue lines do not account for all of its revenue that year. Point In Time was the largest revenue line, at $755.78M or 77.4% of the total, followed by Over Time ($220.22M, 22.6%).
Compared with fiscal 2024, Point In Time grew the fastest, rising 8.3% to $755.78M. Over Time fell the most, down 3.9% to $220.22M.
This breakdown covers every fiscal year from 2019 to 2025, as reported in Sotera Health Co's annual filings.
Sotera Health Co (SHC) breaks its revenue down by region, segment and revenue line. In fiscal 2025, its largest region was United States, with $629.54M or 54.1% of the total, followed by Europe at $232.18M (20.0%).
United States was Sotera Health Co's largest region in fiscal 2025, with $629.54M in revenue, 54.1% of the $1.16B reported across its 4 regions.
Sterigenics was Sotera Health Co's largest segment in fiscal 2025, with $755.78M in revenue, 65.2% of the $1.16B reported across its 3 segments.
Point In Time was Sotera Health Co's largest revenue line in fiscal 2025, with $755.78M in revenue, 77.4% of the $976.00M reported across its 2 revenue lines.
Of the Sotera Health Co regions reported in both fiscal 2024 and fiscal 2025, and making up at least 2% of the total, Europe grew the fastest, rising 18.5% from $196.01M to $232.18M.
Every figure is taken from Sotera Health Co's annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by region covers fiscal 2019 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.